Corvus Pharmaceuticals, Inc. — Investor Relations & Filings

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for immune diseases and cancer. The company focuses on pioneering ITK (Interleukin-2-inducible T-cell kinase) inhibition as a new approach to modulate and control signaling pathways within the immune system. Its lead product candidate, soquelitinib, is a first-in-class, oral therapy that selectively inhibits ITK and is being developed for the treatment of T-cell lymphomas and other immune-related conditions. Corvus is advancing a pipeline of clinical-stage programs with differentiated mechanisms of action designed to precisely target critical immune pathways.